913 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Wetzel Investment Advisors Inc.

Wetzel Investment Advisors Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 913 shares of the biopharmaceutical company’s stock, valued at approximately $74,000.

Several other institutional investors have also recently made changes to their positions in the stock. PCA Investment Advisory Services Inc. acquired a new position in Gilead Sciences during the second quarter worth $25,000. Tompkins Financial Corp raised its holdings in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the last quarter. OFI Invest Asset Management bought a new position in Gilead Sciences in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC bought a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Finally, Sanctuary Wealth Management L.L.C. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on GILD shares. Barclays cut their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Wells Fargo & Company dropped their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research report on Friday. Finally, Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $84.71.

Read Our Latest Analysis on Gilead Sciences

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $66.76 on Friday. Gilead Sciences, Inc. has a 1 year low of $65.90 and a 1 year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The business has a fifty day simple moving average of $71.96 and a two-hundred day simple moving average of $76.56. The company has a market capitalization of $83.12 billion, a P/E ratio of 14.84, a P/E/G ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.67 earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.61%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.